NovAliX enters into fragment-based drug discovery alliance with Kyowa Hakko Kirin

17-Jan-2013 - France

NovAliX SAS announced that it has entered into a fragment-based drug discovery alliance with Kyowa Hakko Kirin Co., Ltd., Japan.

Within the alliance, the companies will collaborate to develop novel drug candidates against protein-protein interaction targets.

Under the terms of the agreement NovAliX will receive technology access fees as well as further research funding payments and milestones.

Other news from the department research and development

Most read news

More news from our other portals

So close that even
molecules turn red...